A real‐world data of Immune checkpoint inhibitors in solid tumors from India

BACKGROUND: Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibility, adverse event rates, compliance, progression...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Med
Prif Awduron: Noronha, Vanita, Abraham, George, Patil, Vijay, Joshi, Amit, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Jain, Srushti, Talreja, Vikas T, Kapoor, Akhil, Kumar Singh, Gunjesh, Khaddar, Satvik, Gupta, Kushal, Rathinasamy, Narmadha, Srinivas, Sujay, Agrawal, Amit, Ventrapati, Pradeep, Prabhash, Kumar
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2021
Pynciau:
Clinical Cancer Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940210/
https://ncbi.nlm.nih.gov/pubmed/33591635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3617
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg